Drug Trial Radar · NCT07922096
A First-in-human Study of SMP-656 in Subjects With Locally Advanced/ Metastatic HER2 Expressing or Mutated Solid Tumors
Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
35
Actual
Start
Feb 1, 2024
Primary completion
Apr 30, 2026
Study completion Apr 30, 2026
Sponsor
- Lead sponsor
- Chengdu SciMount Pharmatech Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 6, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, first-in-human (FIH), phase 1 dose-escalation and cohort expansion study of SMP-656 in subjects with locally advanced/metastatic HER2 expressing or HER2-mutated solid tumors. The study consists of 2 parts: dose-escalation (Part 1) and cohort expansion (Part 2). Part 1 consists of dose escalation cohorts for determining the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D). Part 2 consists of expansion cohorts, including but not limited to breast cancer, non-small cell lung cancer, gynecologic, gastrointestinal and other solid tumors. A total of 35 participants were enrolled between February 2024 and April 2026. The trial has been completed.
Conditions
- HER2-Expressing Advanced Solid Tumors
- HER2-Mutated Advanced Solid Tumors
- Metastatic Solid Tumors
Interventions
SMP-656 InjectionDrug
SMP-656 was supplied as a 50 mg/vial injection for intravenous infusion and given Q3W at 0.5, 1.0, 1.5, 2.0, 2.5 or 3.0 mg/kg during dose escalation and at the selected dose level(s) during dose expansion. Treatment continues until disease progression, intolerable toxicity, voluntary withdrawal, death or trial termination.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Dose-Limiting Toxicity (DLT)Time frame: 21 days after the first dose of SMP-656
- Maximum Tolerated Dose (MTD) and/or Recommended Phase II Dose (RP2D)Time frame: Through study completion, up to 27 months from first dose
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Beijing Cancer Hospital
Beijing, Beijing Municipality, China
Fujian Cancer Hospital
Fuzhou, Fujian, China
Jilin Cancer Hospital
Changchun, Jilin, China
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.